Canadian Federal Court has ruled in the favor of Pfizer, backing Pfizer move to block Novopharm from launching a generic version of Lipitor until its Canadian Patent # 2,021,546 (the ‘546 patent) expires in July 2010. The ruling is subject to appeal. Novopharma is Canadian Unit of Teva Pharmaceutical Industries Ltd.
No comments:
Post a Comment